HRP20171738T1 - Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede - Google Patents
Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede Download PDFInfo
- Publication number
- HRP20171738T1 HRP20171738T1 HRP20171738TT HRP20171738T HRP20171738T1 HR P20171738 T1 HRP20171738 T1 HR P20171738T1 HR P20171738T T HRP20171738T T HR P20171738TT HR P20171738 T HRP20171738 T HR P20171738T HR P20171738 T1 HRP20171738 T1 HR P20171738T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- reperfusion injury
- ischemia
- hours
- prevention
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract 5
- 208000012947 ischemia reperfusion injury Diseases 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 4
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940110272 plasma derived c1-inhibitor Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 230000010410 reperfusion Effects 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Claims (4)
1. Upotreba inhibitora C1 koji ima sniženu razinu terminalnih ostataka sijalinske kiseline u usporedbi s inhibitorom C1 dobivenim iz plazme, naznačena time što snižena razina terminalnih ostataka sijalinske kiseline rezultira poluvijekom u plazmi kraćim od 6 sata, prilikom priprave farmaceutskog pripravka za sprječavanje, smanjivanje ili liječenje ishemijsko-reperfuzijske ozljede, gdje se inhibitor C1 primjenjuje najviše 3 sata, 2 sata, 1 sat ili 30 minuta prije najmanje jednog predviđenog slučaja ishemijsko-reperfuzijske ozljede.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je navedeni predviđeni slučaj ishemijsko-reperfuzijske ozljede presađivanje organa.
3. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačena time što se navedeni inhibitor C1 primjenjuje kontinuirano na subjektu kojem je to potrebno.
4. Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se navedeni inhibitor C1 primjenjuje na organu koji treba presaditi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05112630 | 2005-12-21 | ||
| US76094406P | 2006-01-23 | 2006-01-23 | |
| EP11172880.4A EP2380587B1 (en) | 2005-12-21 | 2006-12-19 | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171738T1 true HRP20171738T1 (hr) | 2018-01-26 |
Family
ID=38016640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110622T HRP20110622T1 (hr) | 2005-12-21 | 2011-08-25 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
| HRP20171738TT HRP20171738T1 (hr) | 2005-12-21 | 2017-11-13 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110622T HRP20110622T1 (hr) | 2005-12-21 | 2011-08-25 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8071532B2 (hr) |
| EP (2) | EP2380587B1 (hr) |
| JP (2) | JP5394748B2 (hr) |
| KR (1) | KR101508668B1 (hr) |
| AT (1) | ATE516043T1 (hr) |
| AU (1) | AU2006327989B2 (hr) |
| CA (1) | CA2632400C (hr) |
| CY (2) | CY1112452T1 (hr) |
| DK (1) | DK2380587T3 (hr) |
| HR (2) | HRP20110622T1 (hr) |
| IL (2) | IL192180A (hr) |
| NZ (1) | NZ568749A (hr) |
| PL (2) | PL1965831T3 (hr) |
| SI (1) | SI2380587T1 (hr) |
| WO (1) | WO2007073186A2 (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
| PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
| EP3028716B1 (en) * | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
| JP5423266B2 (ja) * | 2009-09-14 | 2014-02-19 | 富士電機株式会社 | デジタル制御スイッチング電源装置 |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| CA2829037C (en) * | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| ES2714999T3 (es) | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| JP6127063B2 (ja) * | 2011-12-22 | 2017-05-10 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用 |
| WO2014008242A1 (en) * | 2012-07-03 | 2014-01-09 | The Trustees Of Columbia University In The City Of New York | The use of interleukin-11 to protect against ischemia and reperfusion injury |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
| EP2964255B1 (en) * | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
| EP2968434B1 (en) | 2013-03-15 | 2017-06-28 | Shire Viropharma Incorporated | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |
| EP3013366B1 (en) * | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| ES2788697T3 (es) * | 2014-11-03 | 2020-10-22 | Thrombolytic Science Llc | Métodos y composiciones para trombólisis segura y eficaz |
| US10729767B2 (en) | 2015-04-06 | 2020-08-04 | Bioverativ Usa Inc. | Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage |
| WO2016196070A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
| JP7189767B2 (ja) * | 2015-11-19 | 2022-12-14 | 武田薬品工業株式会社 | 組換えヒトｃ１エステラーゼインヒビター及びその使用 |
| CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| AU2017316513A1 (en) | 2016-08-23 | 2019-03-28 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency |
| US11154596B2 (en) | 2017-06-16 | 2021-10-26 | Thrombolytic Science, Llc | Methods for thrombolysis |
| CA3075686A1 (en) | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| EP3758739B1 (en) | 2018-02-28 | 2024-05-15 | Pharming Intellectual Property B.V. | Treatment and prevention of pre-eclampsia |
| JP2022505307A (ja) | 2018-10-17 | 2022-01-14 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１－ｉｎｈを精製する方法 |
| US20220363715A1 (en) | 2019-07-04 | 2022-11-17 | Csl Behring Gmbh | Process for Purifying C1-INH |
| KR102191500B1 (ko) | 2020-03-30 | 2020-12-15 | 국립낙동강생물자원관 | 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| KR102217607B1 (ko) | 2020-06-01 | 2021-02-18 | 국립낙동강생물자원관 | 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| KR102191452B1 (ko) | 2020-06-30 | 2020-12-15 | 주식회사 에이치비헬스케어 | 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| CA3198740A1 (en) | 2020-11-20 | 2022-05-27 | John Roberts | Method for treating antibody-mediated rejection |
| EP4366761A1 (en) | 2021-07-09 | 2024-05-15 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1402897E (pt) | 1999-05-14 | 2007-01-31 | Jens Christian Jensenius | Novas indicações de lectina de ligação a manana (mbl) no tratamento de indivíduos imunocomprometidos |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| JP2003521914A (ja) * | 2000-01-31 | 2003-07-22 | ファーミング インテレクチュアル プロパティー ベー．フェー． | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
| JP2004100982A (ja) * | 2002-09-05 | 2004-04-02 | Denso Corp | 熱交換器 |
| CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
| PL1626736T3 (pl) * | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
| PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
-
2006
- 2006-12-19 PL PL06824316T patent/PL1965831T3/pl unknown
- 2006-12-19 AT AT06824316T patent/ATE516043T1/de active
- 2006-12-19 US US12/158,987 patent/US8071532B2/en active Active
- 2006-12-19 EP EP11172880.4A patent/EP2380587B1/en active Active
- 2006-12-19 SI SI200632219T patent/SI2380587T1/en unknown
- 2006-12-19 JP JP2008547134A patent/JP5394748B2/ja active Active
- 2006-12-19 NZ NZ568749A patent/NZ568749A/en unknown
- 2006-12-19 AU AU2006327989A patent/AU2006327989B2/en active Active
- 2006-12-19 PL PL11172880T patent/PL2380587T3/pl unknown
- 2006-12-19 KR KR1020087017880A patent/KR101508668B1/ko active IP Right Grant
- 2006-12-19 CA CA2632400A patent/CA2632400C/en active Active
- 2006-12-19 EP EP06824316A patent/EP1965831B1/en active Active
- 2006-12-19 DK DK11172880.4T patent/DK2380587T3/en active
- 2006-12-19 WO PCT/NL2006/050321 patent/WO2007073186A2/en active Application Filing
-
2008
- 2008-06-15 IL IL192180A patent/IL192180A/en active IP Right Grant
-
2011
- 2011-08-25 HR HR20110622T patent/HRP20110622T1/hr unknown
- 2011-10-05 CY CY20111100950T patent/CY1112452T1/el unknown
- 2011-10-11 US US13/271,107 patent/US8415288B2/en active Active
-
2013
- 2013-02-04 JP JP2013019186A patent/JP2013126992A/ja active Pending
- 2013-02-25 US US13/776,529 patent/US9211318B2/en active Active
- 2013-10-17 IL IL228954A patent/IL228954A/en active IP Right Grant
-
2017
- 2017-11-13 HR HRP20171738TT patent/HRP20171738T1/hr unknown
-
2018
- 2018-01-10 CY CY20181100029T patent/CY1119818T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171738T1 (hr) | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede | |
| SG159385A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| PT1268519E (pt) | Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c | |
| WO2007016476A3 (en) | Hepatitis c serine protease inhibitors and uses therefor | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| NO20072286L (no) | Hemming av HCV NS3-NS4A-protease | |
| EP2448410A4 (en) | TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS | |
| JP2004075682A5 (hr) | ||
| NO20081012L (no) | Serin proteaseinhibitorer | |
| IS8617A (is) | Lyfjasamsetning sem samanstendur af tetrahýdrótríasóló (4,3-a)pýrasíni | |
| WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| TW200517389A (en) | Biaryloxymethylarenecarboxylic acids | |
| NO20061426L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| ATE495743T1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
| NO20082108L (no) | Asparaginsyrebaserte proteaseinhibitor | |
| ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
| EP2039367A4 (en) | PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES | |
| NZ596043A (en) | Allergy inhibitor compositions and kits and methods of using the same | |
| JP2004511492A5 (hr) | ||
| WO2009067225A3 (en) | Boceprevir derivatives for the treatment of hcv infections | |
| BR0213099A (pt) | Compostos policìclicos de 5 membros substituìdos úteis para inibição seletiva da cascata de coagulação | |
| WO2007028133A3 (en) | Treatment and prevention of vascular dementia | |
| DK1049480T3 (da) | Antiviralt middel af planteoprindelse | |
| RS20060505A (en) | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |